BioSpace News Archive

Viela Bio (Nasdaq:VIE), a clinical-stage biotechnology company pioneering treatments for autoimmune and severe inflammatory disease, today reported financial results and provided program highlights for the first quarter ended March 31, 2020.

Phoenix Tissue Repair, Inc. (PTR), an affiliate company of BridgeBio Pharma, Inc. (Nasdaq: BBIO) today announced updates to its ongoing Phase 1/2 study of PTR-01 (BridgeBio designation BBP-589), an intravenously-administered recombinant collagen 7 protein replacement therapy for patients with recessive dystrophic epidermolysis bullosa (RDEB).

Ra Medical Systems, Inc. (NYSE: RMED), a medical device company focusing on commercializing excimer laser systems to treat vascular and dermatological diseases, reports financial results for the three months ended March 31, 2020 and provides a business update.

Molecular Templates, Inc., a clinical-stage biopharmaceutical company focused on the discovery and development of the company’s proprietary engineered toxin bodies, which are differentiated, targeted, biologic therapeutics for cancer and other serious diseases, announced that management will participate in the Bank of America Securities Virtual Healthcare Conference and the UBS Virtual Healthcare Conference.

Titan Medical Inc., a medical device company focused on the design and development of a single-port robotic surgical system for application in minimally invasive surgery, announces financial results for the three months ended March 31, 2020.

Mersana Therapeutics, Inc. announced that it will present interim data from the ongoing Phase 1 expansion evaluating XMT-1536, its first-in-class ADC candidate targeting NaPi2b, in patients with ovarian cancer and non-small cell lung adenocarcinoma.

Immunomedics, Inc. announced that its recently FDA-approved ADC, Trodelvy, showed clinical activity in cisplatin-ineligible patients with metastatic urothelial cancer and in patients with previously-treated metastatic endometrial cancer.

Bio-Path Holdings, Inc.,, a biotechnology company leveraging its proprietary DNAbilize™ liposomal delivery and antisense technology to develop a portfolio of targeted nucleic acid cancer drugs, announced an upcoming virtual poster presentation at the 2020 American Society of Clinical Oncology Annual Meeting, taking place from May 29-31, 2020.

Oral presentation to highlight clinical data for tipifarnib in HRAS mutant solid tumors, including overall survival data in head and neck squamous cell carcinoma

Iovance Biotherapeutics, Inc., a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, announced new interim data from Cohort 2 in the C-144-01 study of lifileucel in advanced melanoma.